GT601 / Grit Biotechnology - LARVOL DELTA

Trial in Progress: First in Human Study of GT601, a Next-Generation Neoantigen Cancer Vaccine for Hepatocellular Carcinoma (SITC 2025) - "GT601 will be administered intravenously between 8 to 12 weeks post-surgery, with timing determined by the investigator based on the participant's recovery status. The trial is currently open and enrolling patients."

First-in-human • P1 data • Tumor-specific neoantigens • Hepatocellular Cancer • Oncology • Solid Tumor